NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

You can't put words in her mouth or say she meant something else.

Show me where I put words in Smyth's mouth. I quoted her directly and responded to the framing she used. You're the one interpreting what she "meant"- not me. Smyth wasn’t making a regulatory declaration; she was answering a question using the same language the questioner used: “an immunotherapy for glioblastoma.” That’s not a limitation of the therapy- it’s a reflection of the question’s scope.

You’ve already acknowledged the following statement is true:

DCVax-L is built on a patient-specific, tumor-targeted mechanism: dendritic cells are extracted from the patient’s blood and “educated” using lysate from that patient’s own tumor tissue. These trained cells are then reintroduced to stimulate a targeted immune response- not against a generic cancer type, but against the unique antigens of that individual’s tumor. That’s why DCVax-L is considered cancer agnostic. It doesn’t rely on markers unique to glioblastoma- or any specific tissue type. It targets tumor-specific antigens derived from each patient’s tumor, regardless of origin.

So why won’t you acknowledge that this mechanism directly supports the position that DCVax-L is cancer agnostic?

As for the MHRA’s scope- did you see the full MAA submission? Do you know what data beyond the Phase 3 trial was included? Furthermore, if the MHRA can’t expand beyond the applied indication, then explain how DCVax-L ended up on the High-Cost Drug list with an expanded indication. That didn’t happen by accident.